Stenotrophomonas maltophilia: Difference between revisions
From IDWiki
Stenotrophomonas maltophilia
No edit summary |
m (Text replacement - "[[Cellular shape::" to "[[Shape::") |
||
(11 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
== |
==Background== |
||
===Microbiology=== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
*Multiple mechanisms of resistance |
|||
**RND, MfsA, and Sme-related efflux pumps |
|||
**''Sul'' or ''dfrA'' genes (TMP-SMX resistance) |
|||
**β-lactamases |
|||
**Aminoglycoside-modifying enzymes |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
** [[Levofloxacin]] (and other FQs) |
|||
** [[TMP-SMX]] (Septra) |
|||
** [[Doxycycline]] |
|||
** Maybe also ticarcillin-clavulanate and [[ceftazidime]] |
|||
⚫ | |||
*Therapy should be guided by antimicrobial susceptibility testing |
|||
*Antistenotrophomonal antibiotics: |
|||
**[[Is treated by::TMP-SMX]] 15 mg/kg split q8h (preferred agent, if susceptible) |
|||
**[[Is treated by::Fluoroquinolones]], including [[Is treated by::moxifloxacin]], [[Is treated by::levofloxacin]], and [[Is treated by::ciprofloxacin]] (though develops resistance quickly on monotherapy) |
|||
**[[Is treated by::Minocycline]], [[Is treated by::doxycycline]], and [[Is treated by::tigecycline]] |
|||
**[[Is treated by::Ticarcillin-clavulanate]] and [[Is treated by::ampicillin-sulbactam]] |
|||
**[[Is treated by::Ceftazidime]] and [[Is treated by::ceftazidime-avibactam]] |
|||
**[[Is treated by::Colistin]], though high rates of resistance |
|||
**Possibly [[Is treated by::ceftriaxone]] |
|||
{{DISPLAYTITLE:''Stenotrophomonas maltophilia''}} |
|||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
Latest revision as of 18:24, 13 October 2020
Background
Microbiology
- Aerobic, non-fermentive, catalase positive, oxidase negative, Gram-negative bacillus
- Multiple mechanisms of resistance
- RND, MfsA, and Sme-related efflux pumps
- Sul or dfrA genes (TMP-SMX resistance)
- β-lactamases
- Aminoglycoside-modifying enzymes
Clinical Manifestations
- Nosocomial infections with high mortality and high antibiotic resistance
Management
- Limited antibiotic options
- Therapy should be guided by antimicrobial susceptibility testing
- Antistenotrophomonal antibiotics:
- TMP-SMX 15 mg/kg split q8h (preferred agent, if susceptible)
- Fluoroquinolones, including moxifloxacin, levofloxacin, and ciprofloxacin (though develops resistance quickly on monotherapy)
- Minocycline, doxycycline, and tigecycline
- Ticarcillin-clavulanate and ampicillin-sulbactam
- Ceftazidime and ceftazidime-avibactam
- Colistin, though high rates of resistance
- Possibly ceftriaxone